Three-year cardiovascular events and disease progress in patients with peripheral arterial disease

Results from the Japan Medication Therapy for Peripheral Arterial Disease (J-METHOD)

H. Shigematsu, T. Nishibe, Y. Obitsu, K. Matsuzaki, A. Ishida, T. Miyata, S. Shindo, K. Hida, T. Ohta, M. Ando, T. Kawasaki, T. Yasugi, takuya matsumoto

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Aim. To investigate the current status of peripheral arterial disease (PAD) drug treatment in Japan, and the effects of drug treatment, risk factors, and complications on disease progress and onset of cardiovascular events in PAD patients. Methods. In this prospective observational cohort study, 557 PAD patients were followed up for 3 years, and the current status of PAD treatment, risk factors, and cardiovascular events were monitored. Results. Three drugs, i.e., beraprost sodium, cilostazol, and aspirin, were most frequently used. The patients who had undergone vascular reconstruction of the lower limbs before enrollment showed significant improvement in ABI. Among the patients who had not undergone vascular reconstruction before enrollment, there was a significant improvement in ABI after treatment with beraprost. During the observation period, cardiovascular deaths occurred in 35 patients (6.3%), heart diseases in 63 (11.3%), brain diseases in 39 (7.0%), and events in the lower limbs in 94 (16.9%). The factors affecting the increase of the cardiovascular events were explored by multivariate analysis (Cox regression analysis). As a result, age (75 years or older), ischemic heart disease and increase in severity on the Fontaine classification were identified as significant factors for cardiovascular deaths, whereas kidney disorders and increase in severity on the Fontaine classification were identified for heart diseases, the number of oral drugs for treating PAD was identified for brain diseases, and age (younger than 75 years), dialysis, ABI (less than 0.7) and aspirin were identified for the events in the lower limbs. Conclusion. As a result of the three-year follow-up on the Japanese PAD cohort, the current status of PAD treatment, risk factors, and cardiovascular events could be identified.

Original languageEnglish
Pages (from-to)2-13
Number of pages12
JournalInternational Angiology
Volume29
Issue number2 SUPPL. 1
Publication statusPublished - Apr 1 2010

Fingerprint

Peripheral Arterial Disease
Japan
Cardiovascular Diseases
beraprost
Lower Extremity
Brain Diseases
Pharmaceutical Preparations
Therapeutics
Aspirin
Blood Vessels
Heart Diseases
Observational Studies
Myocardial Ischemia
Dialysis
Cohort Studies
Multivariate Analysis
Regression Analysis
Observation
Kidney

All Science Journal Classification (ASJC) codes

  • Cardiology and Cardiovascular Medicine

Cite this

Three-year cardiovascular events and disease progress in patients with peripheral arterial disease : Results from the Japan Medication Therapy for Peripheral Arterial Disease (J-METHOD). / Shigematsu, H.; Nishibe, T.; Obitsu, Y.; Matsuzaki, K.; Ishida, A.; Miyata, T.; Shindo, S.; Hida, K.; Ohta, T.; Ando, M.; Kawasaki, T.; Yasugi, T.; matsumoto, takuya.

In: International Angiology, Vol. 29, No. 2 SUPPL. 1, 01.04.2010, p. 2-13.

Research output: Contribution to journalArticle

Shigematsu, H, Nishibe, T, Obitsu, Y, Matsuzaki, K, Ishida, A, Miyata, T, Shindo, S, Hida, K, Ohta, T, Ando, M, Kawasaki, T, Yasugi, T & matsumoto, T 2010, 'Three-year cardiovascular events and disease progress in patients with peripheral arterial disease: Results from the Japan Medication Therapy for Peripheral Arterial Disease (J-METHOD)', International Angiology, vol. 29, no. 2 SUPPL. 1, pp. 2-13.
Shigematsu, H. ; Nishibe, T. ; Obitsu, Y. ; Matsuzaki, K. ; Ishida, A. ; Miyata, T. ; Shindo, S. ; Hida, K. ; Ohta, T. ; Ando, M. ; Kawasaki, T. ; Yasugi, T. ; matsumoto, takuya. / Three-year cardiovascular events and disease progress in patients with peripheral arterial disease : Results from the Japan Medication Therapy for Peripheral Arterial Disease (J-METHOD). In: International Angiology. 2010 ; Vol. 29, No. 2 SUPPL. 1. pp. 2-13.
@article{7b01f94312c14be69f7f0ba372e948ee,
title = "Three-year cardiovascular events and disease progress in patients with peripheral arterial disease: Results from the Japan Medication Therapy for Peripheral Arterial Disease (J-METHOD)",
abstract = "Aim. To investigate the current status of peripheral arterial disease (PAD) drug treatment in Japan, and the effects of drug treatment, risk factors, and complications on disease progress and onset of cardiovascular events in PAD patients. Methods. In this prospective observational cohort study, 557 PAD patients were followed up for 3 years, and the current status of PAD treatment, risk factors, and cardiovascular events were monitored. Results. Three drugs, i.e., beraprost sodium, cilostazol, and aspirin, were most frequently used. The patients who had undergone vascular reconstruction of the lower limbs before enrollment showed significant improvement in ABI. Among the patients who had not undergone vascular reconstruction before enrollment, there was a significant improvement in ABI after treatment with beraprost. During the observation period, cardiovascular deaths occurred in 35 patients (6.3{\%}), heart diseases in 63 (11.3{\%}), brain diseases in 39 (7.0{\%}), and events in the lower limbs in 94 (16.9{\%}). The factors affecting the increase of the cardiovascular events were explored by multivariate analysis (Cox regression analysis). As a result, age (75 years or older), ischemic heart disease and increase in severity on the Fontaine classification were identified as significant factors for cardiovascular deaths, whereas kidney disorders and increase in severity on the Fontaine classification were identified for heart diseases, the number of oral drugs for treating PAD was identified for brain diseases, and age (younger than 75 years), dialysis, ABI (less than 0.7) and aspirin were identified for the events in the lower limbs. Conclusion. As a result of the three-year follow-up on the Japanese PAD cohort, the current status of PAD treatment, risk factors, and cardiovascular events could be identified.",
author = "H. Shigematsu and T. Nishibe and Y. Obitsu and K. Matsuzaki and A. Ishida and T. Miyata and S. Shindo and K. Hida and T. Ohta and M. Ando and T. Kawasaki and T. Yasugi and takuya matsumoto",
year = "2010",
month = "4",
day = "1",
language = "English",
volume = "29",
pages = "2--13",
journal = "International Angiology",
issn = "0392-9590",
publisher = "Edizioni Minerva Medica S.p.A.",
number = "2 SUPPL. 1",

}

TY - JOUR

T1 - Three-year cardiovascular events and disease progress in patients with peripheral arterial disease

T2 - Results from the Japan Medication Therapy for Peripheral Arterial Disease (J-METHOD)

AU - Shigematsu, H.

AU - Nishibe, T.

AU - Obitsu, Y.

AU - Matsuzaki, K.

AU - Ishida, A.

AU - Miyata, T.

AU - Shindo, S.

AU - Hida, K.

AU - Ohta, T.

AU - Ando, M.

AU - Kawasaki, T.

AU - Yasugi, T.

AU - matsumoto, takuya

PY - 2010/4/1

Y1 - 2010/4/1

N2 - Aim. To investigate the current status of peripheral arterial disease (PAD) drug treatment in Japan, and the effects of drug treatment, risk factors, and complications on disease progress and onset of cardiovascular events in PAD patients. Methods. In this prospective observational cohort study, 557 PAD patients were followed up for 3 years, and the current status of PAD treatment, risk factors, and cardiovascular events were monitored. Results. Three drugs, i.e., beraprost sodium, cilostazol, and aspirin, were most frequently used. The patients who had undergone vascular reconstruction of the lower limbs before enrollment showed significant improvement in ABI. Among the patients who had not undergone vascular reconstruction before enrollment, there was a significant improvement in ABI after treatment with beraprost. During the observation period, cardiovascular deaths occurred in 35 patients (6.3%), heart diseases in 63 (11.3%), brain diseases in 39 (7.0%), and events in the lower limbs in 94 (16.9%). The factors affecting the increase of the cardiovascular events were explored by multivariate analysis (Cox regression analysis). As a result, age (75 years or older), ischemic heart disease and increase in severity on the Fontaine classification were identified as significant factors for cardiovascular deaths, whereas kidney disorders and increase in severity on the Fontaine classification were identified for heart diseases, the number of oral drugs for treating PAD was identified for brain diseases, and age (younger than 75 years), dialysis, ABI (less than 0.7) and aspirin were identified for the events in the lower limbs. Conclusion. As a result of the three-year follow-up on the Japanese PAD cohort, the current status of PAD treatment, risk factors, and cardiovascular events could be identified.

AB - Aim. To investigate the current status of peripheral arterial disease (PAD) drug treatment in Japan, and the effects of drug treatment, risk factors, and complications on disease progress and onset of cardiovascular events in PAD patients. Methods. In this prospective observational cohort study, 557 PAD patients were followed up for 3 years, and the current status of PAD treatment, risk factors, and cardiovascular events were monitored. Results. Three drugs, i.e., beraprost sodium, cilostazol, and aspirin, were most frequently used. The patients who had undergone vascular reconstruction of the lower limbs before enrollment showed significant improvement in ABI. Among the patients who had not undergone vascular reconstruction before enrollment, there was a significant improvement in ABI after treatment with beraprost. During the observation period, cardiovascular deaths occurred in 35 patients (6.3%), heart diseases in 63 (11.3%), brain diseases in 39 (7.0%), and events in the lower limbs in 94 (16.9%). The factors affecting the increase of the cardiovascular events were explored by multivariate analysis (Cox regression analysis). As a result, age (75 years or older), ischemic heart disease and increase in severity on the Fontaine classification were identified as significant factors for cardiovascular deaths, whereas kidney disorders and increase in severity on the Fontaine classification were identified for heart diseases, the number of oral drugs for treating PAD was identified for brain diseases, and age (younger than 75 years), dialysis, ABI (less than 0.7) and aspirin were identified for the events in the lower limbs. Conclusion. As a result of the three-year follow-up on the Japanese PAD cohort, the current status of PAD treatment, risk factors, and cardiovascular events could be identified.

UR - http://www.scopus.com/inward/record.url?scp=77953257447&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77953257447&partnerID=8YFLogxK

M3 - Article

VL - 29

SP - 2

EP - 13

JO - International Angiology

JF - International Angiology

SN - 0392-9590

IS - 2 SUPPL. 1

ER -